Skip to main content
. 2026 Sep 16;6:1929035. doi: 10.3389/fddev.2026.1929035

FIGURE 4.

Infographic divided into four labeled panels summarizing a nanomaterial’s attributes for cardiac therapy. First panel: illustration of an 83.9 nanometer particle, zeta potential negative thirty-two point one millivolts, rapid three second gelation indicated. Second panel: drug release kinetics under oxidative stress, showing sixty-eight percent release with hydrogen peroxide, twenty-four percent with PBS, and extended twenty-one day triggered release, with enhanced catalytic scavenging versus Fe₃O₄. Third panel: heart illustration showing targeted myocardial accumulation and reduced liver and spleen sequestration. Fourth panel: cardiac performance with treated infarct demonstrating reduced infarct size, improved left ventricular ejection fraction, lower fibrosis, and increased survival rate.

Evidence chain for quantitative validation of ROS-interacting cardiovascular biomaterials. Quantitative evidence should be interpreted sequentially from material characterization to demonstrated responsive behavior, precision delivery, biological action, and cardiac outcome. Particle size, loading, gelation, or catalytic activity establish material performance; ROS-dependent release or degradation establishes stimulus responsiveness; biodistribution, imaging, retention, cellular uptake, or mitochondrial localization establish delivery; and infarct size, LVEF, fibrosis, remodeling, rhythm outcomes, or survival establish therapeutic performance. The strongest evidence connects several levels within the same platform and includes appropriate non-responsive, untargeted, carrier, or free-drug controls (Prepared with the assistance of Gemini NotebookLM pro and OpenAI ChatGPT Plus).